hepatocarcinomas develop
肝癌发展
hepatocarcinomas caused
肝癌引起
primary hepatocarcinomas
原发性肝癌
treating hepatocarcinomas
治疗肝癌
hepatocarcinomas show
肝癌显示
advanced hepatocarcinomas
晚期肝癌
hepatocarcinomas with
肝癌伴
multiple hepatocarcinomas
多发性肝癌
hepatocarcinomas arising
肝癌发生
hepatocarcinomas associated
肝癌相关
advanced hepatocarcinomas often require multimodal treatment approaches.
晚期肝细胞癌通常需要多模式治疗方案。
the prognosis of hepatocarcinomas varies significantly depending on the stage at diagnosis.
肝细胞癌的预后因诊断时分期不同而差异显著。
chronic hepatitis b infection is a major risk factor for developing hepatocarcinomas.
慢性乙型肝炎感染是发生肝细胞癌的主要危险因素。
early detection of hepatocarcinomas improves survival rates substantially.
早期发现肝细胞癌可显著提高生存率。
molecular targeted therapies have shown promise in treating hepatocarcinomas.
分子靶向治疗在治疗肝细胞癌方面已显示出良好的前景。
hepatocarcinomas frequently arise in the setting of cirrhotic livers.
肝细胞癌常在肝硬化背景下发生。
the incidence of hepatocarcinomas has been increasing globally.
肝细胞癌的发病率在全球范围内持续上升。
surgical resection remains the primary treatment option for early-stage hepatocarcinomas.
手术切除仍是早期肝细胞癌的主要治疗选择。
ablation techniques are effective for small hepatocarcinomas.
消融技术对小肝细胞癌有效。
liver transplantation offers curative potential for selected hepatocarcinomas patients.
肝移植为 selected 肝细胞癌患者提供了治愈的可能性。
biomarkers are being studied to improve detection of hepatocarcinomas.
目前正在研究生物标志物以改进肝细胞癌的检测。
vascular invasion is a poor prognostic indicator in hepatocarcinomas.
血管侵犯是肝细胞癌的不良预后指标。
hepatocarcinomas develop
肝癌发展
hepatocarcinomas caused
肝癌引起
primary hepatocarcinomas
原发性肝癌
treating hepatocarcinomas
治疗肝癌
hepatocarcinomas show
肝癌显示
advanced hepatocarcinomas
晚期肝癌
hepatocarcinomas with
肝癌伴
multiple hepatocarcinomas
多发性肝癌
hepatocarcinomas arising
肝癌发生
hepatocarcinomas associated
肝癌相关
advanced hepatocarcinomas often require multimodal treatment approaches.
晚期肝细胞癌通常需要多模式治疗方案。
the prognosis of hepatocarcinomas varies significantly depending on the stage at diagnosis.
肝细胞癌的预后因诊断时分期不同而差异显著。
chronic hepatitis b infection is a major risk factor for developing hepatocarcinomas.
慢性乙型肝炎感染是发生肝细胞癌的主要危险因素。
early detection of hepatocarcinomas improves survival rates substantially.
早期发现肝细胞癌可显著提高生存率。
molecular targeted therapies have shown promise in treating hepatocarcinomas.
分子靶向治疗在治疗肝细胞癌方面已显示出良好的前景。
hepatocarcinomas frequently arise in the setting of cirrhotic livers.
肝细胞癌常在肝硬化背景下发生。
the incidence of hepatocarcinomas has been increasing globally.
肝细胞癌的发病率在全球范围内持续上升。
surgical resection remains the primary treatment option for early-stage hepatocarcinomas.
手术切除仍是早期肝细胞癌的主要治疗选择。
ablation techniques are effective for small hepatocarcinomas.
消融技术对小肝细胞癌有效。
liver transplantation offers curative potential for selected hepatocarcinomas patients.
肝移植为 selected 肝细胞癌患者提供了治愈的可能性。
biomarkers are being studied to improve detection of hepatocarcinomas.
目前正在研究生物标志物以改进肝细胞癌的检测。
vascular invasion is a poor prognostic indicator in hepatocarcinomas.
血管侵犯是肝细胞癌的不良预后指标。
探索常用高频词汇